Price: $82.65, Change: $-0.70, Percent Change: -0.84%
Related Articles
Wire
Cuprina Completes Reverse Split, Seeks Nasdaq Hearing to Avoid Delisting
Cuprina Holdings (CUPR) said it completed a reverse stock split on Wednesday and requested a hearing before a Nasdaq panel in response to a staff determination letter received the same day.The letter notified the company that because it failed to regain compliance with Nasdaq's $1 minimum bid price requirement, its securities will be scheduled for delisting unless it appeals the determination, Cuprina said Friday in a statement.The company filed its hearing request on Thursday.Cuprina said the share consolidation completed Wednesday is expected to bring its bid price back into compliance with the exchange requirement.Price: $2.45, Change: $-0.85, Percent Change: -25.64%
$CUPR
Wire
MannKind Says FDA Approves Afrezza for Children, Adolescents With Diabetes
MannKind (MNKD) said Friday the US Food and Drug Administration approved Afrezza, its inhaled mealtime insulin, for use in children and adolescents aged six and older with type 1 or type 2 diabetes.The approval expands Afrezza's label beyond adults and was supported by results from the phase 3 INHALE-1 study and additional long-term safety and efficacy data, the company said.MannKind said eligible patients can access Afrezza for $35 or less per month through its patient support program.Price: $3.80, Change: $+0.16, Percent Change: +4.40%
$MNKD
Wire
Wedbush Adjusts Price Target on Replimune Group to $6 From $2, Maintains Neutral Rating
Replimune Group (REPL) has an average rating of underweight and mean price target of $2.20, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $8.38, Change: $+3.70, Percent Change: +78.95%
$REPL